Replies to post #110794 on Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

There is NO study that shows any straight numbers on lympro coming from AMBS, to date. That is terribly against the rules. In the first place they pounded that they would be the gold standard for differentiating between AD and non AD dementia after only testing against PD dementia.

THEN that notion went away, and while you CAN get a sen of 90% if you choose a low spec, it remains to be seen if that effort ADDs anything to the research picture.

Also, given that the spec is terribly low, that dictates that the test could only be used in research.

Bottom line, if it IS used in research, it has to compete with serum p tau, and the newer tests coming onboard in the next few years. That will limit its research use.